JP2016536005A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016536005A5 JP2016536005A5 JP2016543983A JP2016543983A JP2016536005A5 JP 2016536005 A5 JP2016536005 A5 JP 2016536005A5 JP 2016543983 A JP2016543983 A JP 2016543983A JP 2016543983 A JP2016543983 A JP 2016543983A JP 2016536005 A5 JP2016536005 A5 JP 2016536005A5
- Authority
- JP
- Japan
- Prior art keywords
- cell population
- test cell
- mitochondrial
- contacting
- outer membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361879869P | 2013-09-19 | 2013-09-19 | |
| US61/879,869 | 2013-09-19 | ||
| PCT/US2014/056284 WO2015042249A1 (en) | 2013-09-19 | 2014-09-18 | Methods of bh3 profiling |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019188457A Division JP2020012850A (ja) | 2013-09-19 | 2019-10-15 | Ｂｈ３プロファイリングの方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016536005A JP2016536005A (ja) | 2016-11-24 |
| JP2016536005A5 true JP2016536005A5 (https=) | 2017-11-02 |
| JP6663852B2 JP6663852B2 (ja) | 2020-03-13 |
Family
ID=52689380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016543983A Active JP6663852B2 (ja) | 2013-09-19 | 2014-09-18 | Ｂｈ３プロファイリングの方法 |
| JP2019188457A Withdrawn JP2020012850A (ja) | 2013-09-19 | 2019-10-15 | Ｂｈ３プロファイリングの方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019188457A Withdrawn JP2020012850A (ja) | 2013-09-19 | 2019-10-15 | Ｂｈ３プロファイリングの方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10739333B2 (https=) |
| EP (1) | EP3047276B1 (https=) |
| JP (2) | JP6663852B2 (https=) |
| AU (1) | AU2014323526B2 (https=) |
| CA (1) | CA2922503C (https=) |
| WO (1) | WO2015042249A1 (https=) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| CN103180318B (zh) | 2010-05-14 | 2017-05-10 | 达那-法伯癌症研究所 | 雄性避孕组合物以及使用方法 |
| PL2902030T3 (pl) | 2010-05-14 | 2017-07-31 | Dana-Farber Cancer Institute, Inc. | Związki tienotriazolodiazepinowe do leczenia nowotworu |
| MX354217B (es) | 2010-05-14 | 2018-02-19 | Dana Farber Cancer Inst Inc | Composiciones y metodos para el tratamiento de leucemia. |
| HK1213046A1 (zh) * | 2012-09-19 | 2016-06-24 | Dana-Farber Cancer Institute, Inc. | 動態bh3分析 |
| AU2014292888B2 (en) | 2013-07-25 | 2018-03-22 | Dana-Farber Cancer Institute, Inc. | Inhibitors of transcription factors and uses thereof |
| CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| CA2929652A1 (en) | 2013-11-08 | 2015-05-14 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (bet) protein inhibitors |
| WO2015117087A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Uses of diazepane derivatives |
| CA2936865A1 (en) | 2014-01-31 | 2015-08-06 | Dana-Farber Cancer Institute, Inc. | Diaminopyrimidine benzenesulfone derivatives and uses thereof |
| SG11201607108XA (en) | 2014-02-28 | 2016-09-29 | Tensha Therapeutics Inc | Treatment of conditions associated with hyperinsulinaemia |
| KR20170032474A (ko) | 2014-08-08 | 2017-03-22 | 다나-파버 캔서 인스티튜트 인크. | 디히드로프테리디논 유도체 및 그의 용도 |
| CN106715437A (zh) | 2014-08-08 | 2017-05-24 | 达纳-法伯癌症研究所股份有限公司 | 二氮杂环庚烷衍生物及其用途 |
| BR112017008714A2 (pt) | 2014-10-27 | 2017-12-19 | Tensha Therapeutics Inc | inibidores de bromodomínio |
| US10793915B2 (en) | 2015-01-12 | 2020-10-06 | Eutropics Pharmaceuticals, Inc. | Context dependent diagnostics test for guiding cancer treatment |
| US9901574B2 (en) | 2015-04-20 | 2018-02-27 | Tolero Pharmaceuticals, Inc. | Predicting response to alvocidib by mitochondrial profiling |
| AU2016253957C1 (en) * | 2015-04-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
| ES2739749T3 (es) | 2015-05-18 | 2020-02-03 | Tolero Pharmaceuticals Inc | Profármacos de alvocidib que tienen biodisponibilidad aumentada |
| US10702527B2 (en) | 2015-06-12 | 2020-07-07 | Dana-Farber Cancer Institute, Inc. | Combination therapy of transcription inhibitors and kinase inhibitors |
| MX2018001289A (es) | 2015-08-03 | 2018-04-30 | Tolero Pharmaceuticals Inc | Terapias de combinacion para el tratamiento del cancer. |
| RU2018112953A (ru) | 2015-09-11 | 2019-10-14 | Дана-Фарбер Кэнсер Инститьют, Инк. | Ацетамидтиенотриазолодиазепины и пути их применения |
| HK1256417A1 (zh) | 2015-09-11 | 2019-09-20 | 达纳-法伯癌症研究所股份有限公司 | 氰基噻吩并三唑并二氮杂环庚三烯及其用途 |
| MX2018006499A (es) | 2015-11-25 | 2018-08-01 | Dana Farber Cancer Inst Inc | Inhibidores de bromodominio bivalentes y usos de los mismos. |
| WO2018094275A1 (en) | 2016-11-18 | 2018-05-24 | Tolero Pharmaceuticals, Inc. | Alvocidib prodrugs and their use as protein kinase inhibitors |
| KR20190099260A (ko) | 2016-12-19 | 2019-08-26 | 톨레로 파마수티컬스, 인크. | 프로파일링 펩티드 및 감도 프로파일링을 위한 방법 |
| WO2019055579A1 (en) | 2017-09-12 | 2019-03-21 | Tolero Pharmaceuticals, Inc. | TREATMENT REGIME FOR CANCERS THAT ARE INSENSITIVE TO BCL-2 INHIBITORS USING THE MCL-1 ALVOCIDIB INHIBITOR |
| US11034710B2 (en) | 2018-12-04 | 2021-06-15 | Sumitomo Dainippon Pharma Oncology, Inc. | CDK9 inhibitors and polymorphs thereof for use as agents for treatment of cancer |
| JP7589159B2 (ja) | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
| US11793802B2 (en) | 2019-03-20 | 2023-10-24 | Sumitomo Pharma Oncology, Inc. | Treatment of acute myeloid leukemia (AML) with venetoclax failure |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| US5670617A (en) | 1989-12-21 | 1997-09-23 | Biogen Inc | Nucleic acid conjugates of tat-derived transport polypeptides |
| US5804604A (en) | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
| EP1690934A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| NZ255101A (en) | 1992-07-24 | 1997-08-22 | Cell Genesys Inc | A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2219361C (en) | 1995-04-27 | 2012-02-28 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
| BR9610058A (pt) | 1995-07-28 | 1999-07-27 | Marie Curie Cancer Care | Uso de vp22 ou uma porção ativa fragmento ou homólogo do mesmo proteína de transporte ácido nucleíco vetor de expressão célula hospedeira de mamíferos ou microbiana e processos para transportar uma proteína ou peptídeo desejado para uma população de marcaç o de células e para transportar uma molécula desejada em uma população de células |
| EP0799422A1 (en) | 1995-10-24 | 1997-10-08 | Sangstat Medical Corporation | Anti alpha-galactosyl screening technique |
| US5965703A (en) | 1996-09-20 | 1999-10-12 | Idun Pharmaceuticals | Human bad polypeptides, encoding nucleic acids and methods of use |
| US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
| WO1999014321A1 (en) | 1997-09-17 | 1999-03-25 | The Walter And Eliza Hall Institute Of Medical Research | Novel therapeutic molecules |
| US20020029391A1 (en) | 1998-04-15 | 2002-03-07 | Claude Geoffrey Davis | Epitope-driven human antibody production and gene expression profiling |
| WO2000059526A1 (en) | 1999-04-07 | 2000-10-12 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| AU6906100A (en) | 1999-08-16 | 2001-03-13 | Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The | Receptor-mediated uptake of an extracellular bcl-xl fusion protein inhibits apoptosis |
| WO2002020568A2 (en) | 2000-09-06 | 2002-03-14 | Abbott Laboratories | Mutant peptides derived from bad and their use to identify substances which bind to a member of the bcl-2 family of proteins |
| WO2002069995A2 (en) | 2001-02-16 | 2002-09-12 | Medical College Of Georgia Research Institute, Inc. | Use of trail and antiprogestins for treating cancer |
| WO2003040168A2 (en) | 2001-11-06 | 2003-05-15 | Enanta Pharmaceuticals, Inc. | Methods and compositions for identifying peptide aptamers capable of altering a cell phenotype |
| WO2003055515A1 (en) | 2001-12-21 | 2003-07-10 | Arius Research, Inc. | Individualized anti-cancer antibodies |
| WO2004022580A2 (en) | 2002-09-09 | 2004-03-18 | Dana-Farber Cancer Institute, Inc. | Bh3 peptides and method of use thereof |
| WO2004058804A1 (en) | 2002-12-24 | 2004-07-15 | Walter And Eliza Hall Institute Of Medical Research | Peptides and therapeutic uses thereof |
| EP1608969A4 (en) | 2003-03-19 | 2007-06-06 | Alfa Wassermann Inc | SEPARATION AND ACCUMULATION OF SUB-CELLULAR COMPONENTS, AND PROTEINS WHICH ARE DRAWN THEREFROM |
| EP1997828B1 (en) | 2003-11-05 | 2017-10-04 | Dana-Farber Cancer Institute, Inc. | Stabilized alpha helical peptides from BCL-2 and uses thereof |
| US7714005B2 (en) | 2004-12-22 | 2010-05-11 | The Ohio State University Research Foundation | Small molecule Bcl-xL/Bcl-2 binding inhibitors |
| JP2005130867A (ja) | 2005-02-16 | 2005-05-26 | Mitokor | ミトコンドリア内カルシウムを使用するスクリーニングアッセイ |
| WO2006099667A1 (en) | 2005-03-21 | 2006-09-28 | The Walter And Eliza Hall Institute Of Medical Research | Prophylactic and therapeutic agents and uses therefor |
| US20070027175A1 (en) * | 2005-07-27 | 2007-02-01 | Shaughnessy John Jr | Antineoplastic activities of ellipticine and its derivatives |
| EP2008106A2 (en) | 2006-03-31 | 2008-12-31 | Dana-Farber Cancer Institute | Methods of determining cellular chemosensitivity |
| US8518635B2 (en) | 2006-06-12 | 2013-08-27 | The J. David Gladstone Institutes | Regulation of protein activity by reversible acetylation |
| KR100786759B1 (ko) | 2006-07-07 | 2007-12-18 | 김현기 | Ｈｃｃｒ-1을 포함하는 유방암 예후 마커 및 비만 유도조성물 |
| WO2008021484A2 (en) | 2006-08-16 | 2008-02-21 | Eutropics Pharmaceuticals | Assay system to identify therapeutic agents |
| WO2008152405A2 (en) | 2007-06-15 | 2008-12-18 | The Queen's University Of Belfast | Protein complexes comprising bh3 peptides and voltage dependent anion channel (vdac) peptides as well as uses thereof for the treatment of proliferative diseases |
| US8466140B2 (en) | 2007-09-10 | 2013-06-18 | University Of Massachusetts | Mitochondria-targeted anti-tumor agents |
| JP5783721B2 (ja) | 2007-09-26 | 2015-09-24 | ダナ ファーバー キャンサー インスティテュート インコーポレイテッド | Ｂｃｌ−２ファミリーポリペプチドを調節する方法及び組成物 |
| JP2009240173A (ja) | 2008-03-28 | 2009-10-22 | Univ Of Tokushima | パーキン蛋白の新規糖化因子 |
| SG176801A1 (en) | 2009-06-11 | 2012-01-30 | Minerva Biotechnologies Corp | Methods for culturing stem and progenitor cells |
| WO2010147961A1 (en) | 2009-06-15 | 2010-12-23 | Precision Therapeutics, Inc. | Methods and markers for predicting responses to chemotherapy |
| US20130122492A1 (en) | 2011-11-14 | 2013-05-16 | Kellbenx Inc. | Detection, isolation and analysis of rare cells in biological fluids |
| KR102062416B1 (ko) | 2012-05-10 | 2020-01-03 | 유트로픽스 파마슈티컬스, 인크. | 실용 가능한 암 진단 대체 법 |
| US20150322479A1 (en) | 2012-06-20 | 2015-11-12 | Cytospan Technologies Corporation | Apparatus and method for quantification of replicative lifespan and observation of senescene |
| HK1213046A1 (zh) * | 2012-09-19 | 2016-06-24 | Dana-Farber Cancer Institute, Inc. | 動態bh3分析 |
| JP6327662B2 (ja) | 2012-09-26 | 2018-05-23 | 学校法人藤田学園 | 細胞表面タンパクを抗原とする抗体を測定する方法 |
| WO2015010094A1 (en) | 2013-07-18 | 2015-01-22 | Eutropics Pharmaceuticals, Inc. | Differential bh3 mitochondrial profiling |
| CA2922503C (en) | 2013-09-19 | 2021-10-26 | Dana-Farber Cancer Institute, Inc. | Methods of bh3 profiling |
| AU2016253957C1 (en) | 2015-04-27 | 2021-04-01 | Dana-Farber Cancer Institute, Inc. | High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells |
| US11092602B2 (en) | 2015-07-06 | 2021-08-17 | Whitehead Institute For Biomedical Research | Methods and compositions relating to proteasome inhibitor resistance |
| JP7589159B2 (ja) | 2019-02-26 | 2024-11-25 | デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド | ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング |
-
2014
- 2014-09-18 CA CA2922503A patent/CA2922503C/en active Active
- 2014-09-18 EP EP14845952.2A patent/EP3047276B1/en active Active
- 2014-09-18 AU AU2014323526A patent/AU2014323526B2/en active Active
- 2014-09-18 WO PCT/US2014/056284 patent/WO2015042249A1/en not_active Ceased
- 2014-09-18 JP JP2016543983A patent/JP6663852B2/ja active Active
- 2014-09-18 US US15/022,987 patent/US10739333B2/en active Active
-
2019
- 2019-10-15 JP JP2019188457A patent/JP2020012850A/ja not_active Withdrawn
-
2020
- 2020-07-02 US US16/919,173 patent/US11867687B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016536005A5 (https=) | ||
| JP2015531606A5 (https=) | ||
| Couvertier et al. | Chemical-proteomic strategies to investigate cysteine posttranslational modifications | |
| MX391457B (es) | Sistema y metodo para matriz de sensores de corona de proteinas para la deteccion temprana de enfermedades. | |
| JP2020012850A5 (https=) | ||
| CY1121741T1 (el) | Χρηση του μεγεθους θραυσματων εξωκυτταριου dna για τον προσδιορισμο παραλλαγης αριθμου αντιγραφων | |
| MX374652B (es) | Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco. | |
| CR20150437A (es) | Construcciones de anticuerpos para cdh19 y cd3 | |
| BR112017025297A2 (pt) | anticorpos anti-gitr para diagnóstico do câncer | |
| BR112016004437A2 (pt) | métodos de imunoteste e de seleção de linhagem de células, anticorpos e kit | |
| JP2018514210A5 (https=) | ||
| EA201792289A1 (ru) | Способы обнаружения агглютинации и композиции для их осуществления | |
| WO2015088927A3 (en) | Access tracking and restriction | |
| MX2020003523A (es) | Deteccion de dimetilarginina simetrica. | |
| JP2017534851A5 (https=) | ||
| Argyropoulos et al. | Forecasting economic activity from yield curve factors | |
| Maas et al. | Strange nucleon form-factors | |
| BR112014012003A2 (pt) | sistema de controle de qualidade, método e meio legível por computador para o uso com bens de consumo, usuários e dispositivos de teste de diagnóstico biológico/ambiental | |
| BR112016021714A2 (pt) | imunoensaio e anticorpos para a detecção de cromogranina a | |
| MX2018004029A (es) | Deteccion de analitos con multiples sustratos. | |
| BR112016015537A2 (pt) | métodos e kits para detectar a presença de sequência polinucleotídea da e. histolytica em amostra | |
| EP3315613A3 (en) | Methods and kits for diagnosing or assessing the risk of cervical cancer | |
| BR112017020539B8 (pt) | Reagente para imunoensaio compreendendo um polipeptídeo, métodos de detecção de anticorpos e/ou antígenos para o vírus da hepatite c em uma amostra biológica, de seleção de amostras biológicas de um suprimento de amostras biológicas humanas, bem como polipeptídeo isolado e kit para teste imunodiagnóstico | |
| Diponegoro | Konseling dalam Islam | |
| BR112015023792A2 (pt) | métodos e aparelhos para identificar perfil de anticorpo em um indivíduo ou uma fonte de material biológico |